A Look Back at Our First Year: Building Therna Biosciences in 2025

We started Therna Biosciences in April 2025 with a simple belief: RNA is a language, and it can be learned and engineered. What has changed since then is not that belief, but the confidence that we are building the tools to make it real.

RNA medicines have already transformed medicine, but the next phase requires deeper control. Control over tissue specificity. Control over durability. Control over safety and expression. Biology has always held these answers, but only recently have we had the computational power and data scale to uncover them. This is the moment Therna Biosciences was built for.

From day one, we set out to integrate deep RNA biology with generative AI in a way that respects biological complexity rather than flattening it. At Therna, we have built an AI platform to design novel RNA medicines that are longer-lasting, safe, and more effective. Our approach is grounded in a lab in the loop system, where models are continuously informed by carefully designed experiments and high quality biological data. Asking the right biological questions has been just as important as building the right models.

What makes Therna Biosciences different is that we are not only an AI company applying models to biology. We are deeply rooted in the data we generate. Our experimental systems are designed to produce biologically meaningful, high resolution datasets that directly shape our models. Better data leads to better models, and better models allow us to ask more precise biological questions. This feedback loop is core to how we operate and why our platform continues to improve with every cycle.

After two years of stealth operation, we launched the company officially this year by securing seed funding from investors (Pear VC, AIX, and Fusion Fund) who believed in our mission and vision. We assembled an experienced team that brings together deep expertise in RNA biology, AI, and translational and preclinical science to streamline the AI-powered discoveries into reality by designing next generation RNA medicines.

We were proud to be accepted into both the NVIDIA Inception program and the Google for Startups Cloud Program. These partnerships reflect the seriousness of our technical ambition and have strengthened the computational foundation behind our work. As part of our collaboration with NVIDIA, we are working with CodonFM, the new RNA foundation model that learns the rules of RNA by reading sequences in biological units called codons to reveal patterns that matter for therapeutic design. Integrating Therna’s proprietary RNA biology data with this class of models and world class compute infrastructure helps accelerate the development of programmable RNA medicines in ways that were not possible before.

Perhaps most importantly, we validated our core premise. RNA is a language, and it can be learned and engineered. With the right data, the right experiments, and the right models, RNA can be designed with intent. Fit for purpose mRNA. Smarter targeting strategies. Faster iteration cycles. Work that once took years can now happen in weeks.

As we look ahead to 2026, the opportunity feels even larger. We are excited to scale our platform, expand the scope of what programmable RNA can do, and translate our advances into medicines that matter. This is still the beginning, but the foundation is strong, and the momentum is real. Therna Biosciences is here to become The RNA company.

Thank you to our team, our partners, and everyone who believes that the future of RNA medicine can be written with purpose.

We are just getting started.